Karyopharm Therapeutics (NASDAQ:KPTI) Releases Earnings Results, Misses Estimates By $0.06 EPS


Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) posted its quarterly earnings results on Sunday. The company reported ($0.77) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.06), MarketWatch Earnings reports. Karyopharm Therapeutics had a negative return on equity of 187.66% and a negative net margin of 221.23%.

KPTI stock traded down $0.96 during mid-day trading on Tuesday, reaching $8.48. 3,754,746 shares of the stock traded hands, compared to its average volume of 2,442,094. The company has a quick ratio of 5.39, a current ratio of 5.42 and a debt-to-equity ratio of 1.38. Karyopharm Therapeutics has a 52 week low of $8.43 and a 52 week high of $21.82. The business has a 50-day moving average of $10.41 and a two-hundred day moving average of $14.01. The firm has a market capitalization of $636.52 million, a PE ratio of -2.94 and a beta of 0.93.

In other Karyopharm Therapeutics news, insider Sharon Shacham sold 4,000 shares of the company’s stock in a transaction dated Thursday, March 18th. The shares were sold at an average price of $12.39, for a total transaction of $49,560.00. Following the completion of the sale, the insider now directly owns 920,152 shares in the company, valued at $11,400,683.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 14,681 shares of company stock valued at $207,959 over the last 90 days. Corporate insiders own 13.26% of the company’s stock.

A number of research firms have recently weighed in on KPTI. Robert W. Baird dropped their price target on shares of Karyopharm Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research note on Tuesday. Royal Bank of Canada decreased their price objective on shares of Karyopharm Therapeutics from $24.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday. Zacks Investment Research cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 18th. Barclays decreased their price objective on shares of Karyopharm Therapeutics from $26.00 to $22.00 and set an “overweight” rating for the company in a report on Friday, February 12th. Finally, SVB Leerink decreased their price objective on shares of Karyopharm Therapeutics from $22.00 to $15.00 and set an “outperform” rating for the company in a report on Monday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. Karyopharm Therapeutics presently has an average rating of “Buy” and a consensus price target of $27.00.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1.

Read More: Market Capitalization – What it Means for Investors

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.